Am. J. Respir. Crit. Care Med., Volume 157, Number 3, March 1998, 907-911

Pulmonary Hypertension in POEMS Syndrome
A New Feature Mediated by Cytokines

PHILIPPE LESPRIT, BERTRAND GODEAU, FRANCOIS-JÉRÔME AUTHIER, MARTIN SOUBRIER, MATHIEU ZUBER, CLAIRE LARROCHE, JEAN-PAUL VIARD, BERTRAND WECHSLER, and ROMAIN GHERARDI

Service de Médecine Interne, and Département de Pathologie (Groupe Nerf-Muscle), Hôpital Henri Mondor, Créteil; Service de Rhumatologie, Hôpital Montpied, Clermont-Ferrand; Service de Neurologie, Hôpital Saint-Anne, Paris; Service de Médecine Interne, Hôpital Avicenne, Bobigny; Service d'Immunologie Clinique, Hôpital Necker, Paris; and Service de Médecine Interne, Hôpital Pitié-Salpétrière, Paris, France

POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome is a rare variant of plasma cell dyscrasia with multiple systemic manifestations. We followed the progress of 20 patients with POEMS syndrome in our institution over a 10-yr period. Pulmonary hypertension (PH) was observed in five patients. All patients suffered dyspnea on exertion, which always appeared during an exacerbation of POEMS syndrome. The typical echocardiographic signs of PH were observed in all of these patients, and the median pulmonary-artery systolic pressure was 57 mm Hg (range, 50 to 65 mm Hg). Mean pulmonary-artery pressure during right side heart catheterization in two patients was 32 mm Hg. No other explanation for the PH could be found. Overproduction of cytokines was found in all cases, with high serum concentrations of interleukin-1, interleukin-6, tumor necrosis factor-, and vascular endothelial growth factor. We suggest that PH should be added to the list of symptoms of POEMS syndrome. Cytokines may mediate POEMS syndrome-associated PH, as proposed for the other systemic manifestations of this disorder.

This article has been cited by other articles:

				L. Kugathasan, J. B. Ray, Y. Deng, E. Rezaei, D. J. Dumont, and D. J. Stewart The angiopietin-1-Tie2 pathway prevents rather than promotes pulmonary arterial hypertension in transgenic mice J. Exp. Med., September 28, 2009; 206(10): 2221 - 2234. [Abstract] [Full Text] [PDF]

				S. J. Wort, M. Ito, P.-C. Chou, S. K. Mc Master, R. Badiger, E. Jazrawi, P. de Souza, T. W. Evans, J. A. Mitchell, L. Pinhu, et al. Synergistic Induction of Endothelin-1 by Tumor Necrosis Factor {alpha} and Interferon {gamma} Is due to Enhanced NF-{kappa}B Binding and Histone Acetylation at Specific {kappa}B Sites J. Biol. Chem., September 4, 2009; 284(36): 24297 - 24305. [Abstract] [Full Text] [PDF]

				T.-M. Yu, Y.-H. Chen, J.-Y. Hsu, C.-S. Sun, Y.-W. Chuang, C.-H. Chen, M.-J. Wu, C.-H. Cheng, and K.-H. Shu Systemic inflammation is associated with pulmonary hypertension in patients undergoing haemodialysis Nephrol. Dial. Transplant., June 1, 2009; 24(6): 1946 - 1951. [Abstract] [Full Text] [PDF]

				M. K. Steiner, O. L. Syrkina, N. Kolliputi, E. J. Mark, C. A. Hales, and A. B. Waxman Interleukin-6 Overexpression Induces Pulmonary Hypertension Circ. Res., January 30, 2009; 104(2): 236 - 244. [Abstract] [Full Text] [PDF]

				J. S. Allam, C. C. Kennedy, T. R. Aksamit, and A. Dispenzieri Pulmonary Manifestations in Patients With POEMS Syndrome: A Retrospective Review of 137 Patients Chest, April 1, 2008; 133(4): 969 - 974. [Abstract] [Full Text] [PDF]

				S. D. Swain, S. Han, A. Harmsen, K. Shampeny, and A. G. Harmsen Pulmonary Hypertension Can Be a Sequela of Prior Pneumocystis Pneumonia Am. J. Pathol., September 1, 2007; 171(3): 790 - 799. [Abstract] [Full Text] [PDF]

				P. Joppa, D. Petrasova, B. Stancak, and R. Tkacova Systemic Inflammation in Patients With COPD and Pulmonary Hypertension. Chest, August 1, 2006; 130(2): 326 - 333. [Abstract] [Full Text] [PDF]

				D. Montani, L. Achouh, A. G. Marcelin, J-P. Viard, O. Hermine, D. Canioni, O. Sitbon, G. Simonneau, and M. Humbert Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman's disease Eur. Respir. J., November 1, 2005; 26(5): 969 - 972. [Abstract] [Full Text] [PDF]

				A. Dispenzieri POEMS Syndrome Hematology, January 1, 2005; 2005(1): 360 - 367. [Abstract] [Full Text] [PDF]

				T. M. Bull, C. D. Coldren, M. Moore, S. M. Sotto-Santiago, D. V. Pham, S. P. Nana-Sinkam, N. F. Voelkel, and M. W. Geraci Gene Microarray Analysis of Peripheral Blood Cells in Pulmonary Arterial Hypertension Am. J. Respir. Crit. Care Med., October 15, 2004; 170(8): 911 - 919. [Abstract] [Full Text] [PDF]

				S. Yaqub, K. G. Moder, and M. Q. Lacy Severe, Reversible Pulmonary Hypertension in a Patient With Monoclonal Gammopathy and Features of Dermatomyositis Mayo Clin. Proc., May 1, 2004; 79(5): 687 - 689. [Abstract] [PDF]

				H. El-Haroun, D. Bradbury, A. Clayton, and A. J. Knox Interleukin-1{beta}, Transforming Growth Factor-{beta}1, and Bradykinin Attenuate Cyclic AMP Production by Human Pulmonary Artery Smooth Muscle Cells in Response to Prostacyclin Analogues and Prostaglandin E2 by Cyclooxygenase-2 Induction and Downregulation of Adenylyl Cyclase Isoforms 1, 2, and 4 Circ. Res., February 20, 2004; 94(3): 353 - 361. [Abstract] [Full Text] [PDF]

				T.M. Bull, C.D. Cool, A.E. Serls, P.R. Rai, J. Parr, J.M. Neid, M.W. Geraci, T.B. Campbell, N.F. Voelkel, and D.B. Badesch Primary pulmonary hypertension, Castleman's disease and human herpesvirus-8 Eur. Respir. J., September 1, 2003; 22(3): 403 - 407. [Abstract] [Full Text] [PDF]

				O. U. Gurkan, C. O'Donnell, R. Brower, E. Ruckdeschel, and P. M. Becker Differential effects of mechanical ventilatory strategy on lung injury and systemic organ inflammation in mice Am J Physiol Lung Cell Mol Physiol, September 1, 2003; 285(3): L710 - L718. [Abstract] [Full Text] [PDF]

				P. Dorfmuller, F. Perros, K. Balabanian, and M. Humbert Inflammation in pulmonary arterial hypertension Eur. Respir. J., August 1, 2003; 22(2): 358 - 363. [Abstract] [Full Text] [PDF]

				D Mukerjee, E Kingdon, M Vanderpump, and J G Coghlan Pathophysiological insights from a case of reversible pulmonary arterial hypertension J R Soc Med, August 1, 2003; 96(8): 403 - 404. [Full Text] [PDF]

				A. Dispenzieri, R. A. Kyle, M. Q. Lacy, S. V. Rajkumar, T. M. Therneau, D. R. Larson, P. R. Greipp, T. E. Witzig, R. Basu, G. A. Suarez, et al. POEMS syndrome: definitions and long-term outcome Blood, April 1, 2003; 101(7): 2496 - 2506. [Abstract] [Full Text] [PDF]

				D. A. Bradbury, R. Newton, Y.-M. Zhu, J. Stocks, L. Corbett, E. D. Holland, L. H. Pang, and A. J. Knox Effect of bradykinin, TGF-beta 1, IL-1beta , and hypoxia on COX-2 expression in pulmonary artery smooth muscle cells Am J Physiol Lung Cell Mol Physiol, October 1, 2002; 283(4): L717 - L725. [Abstract] [Full Text] [PDF]

				K. Balabanian, A. Foussat, P. Dorfmuller, I. Durand-Gasselin, F. Capel, L. Bouchet-Delbos, A. Portier, A. Marfaing-Koka, R. Krzysiek, A.-C. Rimaniol, et al. CX3C Chemokine Fractalkine in Pulmonary Arterial Hypertension Am. J. Respir. Crit. Care Med., May 15, 2002; 165(10): 1419 - 1425. [Abstract] [Full Text] [PDF]

				C. Veyssier-Belot and P. Cacoub Role of endothelial and smooth muscle cells in the physiopathology and treatment management of pulmonary hypertension Cardiovasc Res, November 1, 1999; 44(2): 274 - 282. [Abstract] [Full Text] [PDF]

				B. Mokhlesi and M. Jain Pulmonary Manifestations of POEMS Syndrome: Case Report and Literature Review Chest, June 1, 1999; 115(6): 1740 - 1742. [Abstract] [Full Text] [PDF]